Loading...

FITC anti-human CD16 Antibody

Pricing & Availability
Clone
3G8 (See other available formats)
Regulatory Status
RUO
Workshop
V NK80
Other Names
FcγRIII, Fc gamma receptor, Fc gamma receptor 3
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
3G8_FITC_071805
Human peripheral blood lymphocytes stained with 3G8 FITC
  • 3G8_FITC_071805
    Human peripheral blood lymphocytes stained with 3G8 FITC
See FITC spectral data
Cat # Size Price Save
302005 25 tests ¥17,560
302006 100 tests ¥40,340
Description

CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC).

Product Details
Technical data sheet

Product Details

Reactivity
Human,Cynomolgus,Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Human PMN cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The 3G8 antibody clone blocks neutrophil phagocytosis and stimulates NK cell proliferation. It has been reported that this clone interacts with the FcγRIIa and FcγRIIIb receptors causing neutrophil activation and aggregation18. Due to this phenomenon staining in whole blood may cause a reduction in the number of granulocytes or alter their scatter profile.

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections6, immunoprecipitation3, stimulation of NK cell proliferation4, blocking of phagocytosis5, and blocking of immunoglobulin binding to FcγRIII7,8. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302049, 302050, 302057, 302058).

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  3. Edberg J, et al. 1997. J. Immunol. 159:3849. (IP)
  4. Hoshino S, et al. 1991. Blood 78:3232. (Stim)
  5. Tamm A, et al. 1996. Immunol. 157:1576. (Block)
  6. Da Silva DM, et al. 2001. Int. Immunol. 13:633. (IHC)
  7. Holl V, et al. 2004. J. Immunol. 173:6274. (Block)
  8. Hober D, et al. 2002. J. Gen. Virol. 83:2169. (Block)
  9. Brainard DM, et al. 2009. J. Virol. 83:7305. PubMed
  10. Smed-Sörensen A, et al. 2008. Blood 111:5037. (Block) PubMed
  11. Timmerman KL, et al. 2008. J. Leukoc. Biol. 84:1271. (FC) PubMed
  12. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  13. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
  14. Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC)
  15. Boltz A, et al. 2011. J. Biol Chem. 286:21896. PubMed
  16. Wu Z, et al. 2013. J. Virol. 87:7717. PubMed
  17. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  18. Vossebeld PJ, et al. 1997. Biochem J. 323:87-94 (Stim)
Product Citations
  1. Gärtner K, et al. 2018. Cancer Med. 11:39. PubMed
  2. Osorio FG et al. 2018. Cell reports. 25(9):2308-2316 . PubMed
  3. Wang Y, et al. 2019. J Transl Med. 17:93. PubMed
  4. Tong M, et al. 2019. J Immunol. 203:500. PubMed
  5. Souriant S, et al. 2019. Cell Rep. 26:3586. PubMed
  6. Theurich S et al. 2017. Cell metabolism. 26(1):171-184 . PubMed
  7. Pahl JHW, et al. 2018. Cancer Immunol Res. 0.609027778. PubMed
  8. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  9. Hazenberg MD, et al. 2019. Blood Adv. 2.659722222. PubMed
  10. Nowak W, et al. 2020. EBioMedicine. 50:290-305.. PubMed
  11. Ren C, et al. 2020. J Immunol. 204:1012. PubMed
  12. Seamon K, et al. 2020. Front Immunol. 11:396. PubMed
  13. Wu HL, et al. 2018. J Immunol. 200:49. PubMed
  14. Zhang D, et al. 2020. Oncoimmunology. 9:1744921. PubMed
  15. Mulfaul K, et al. 2020. Cell Rep. 30:2209. PubMed
  16. Sagnella SM, et al. 2020. Cancer Cell. 37(3):354-370. PubMed
  17. Evans RDR, et al. 2020. Nat Commun. 3.491666667. PubMed
  18. Okada T, et al. 2010. Am J Pathol. 176:2309. PubMed
  19. Hunn M, et al. 2012. Clin Cancer Res. 18:6446. PubMed
  20. Xue D, et al. 2013. Transplant Proc. 45:3279. PubMed
  21. Poonia B, Pauza C 2014. PLoS One. 9:88884. PubMed
  22. Søndergaard J, et al. 2014. Int Immunol. 26) : 705-16. PubMed
  23. Bal S, et al. 2016. Nat Immunol. 10.1038/ni.3444. PubMed
  24. Geng S, et al. 2016. Nat Commun. 7:13436. PubMed
  25. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
  26. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
  27. Hasaart KAL, et al. 2020. Sci Rep. 10:12991. PubMed
  28. Vanoni G, et al. 2021. eLife. 10:00. PubMed
  29. Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed
  30. Evren E, et al. 2020. Immunity. 54(2):259-275.e7. PubMed
  31. Zee BM, et al. 2021. iScience. 24(6):102651. PubMed
  32. Cheng Y, et al. 2021. Immunity. 54(8):1825-1840.e7. PubMed
  33. Kobayashi Y, et al. 2020. Int J Oncol. 999:56. PubMed
  34. Witkowski MT, et al. 2020. Cancer Cell. 37:867. PubMed
  35. Kerr SC, et al. 2020. Clin Exp Allergy. 50:904. PubMed
  36. Tong M, et al. 2021. J Immunol. 206:1039. PubMed
  37. Xu Y, et al. 2021. Stem Cell Res Ther. 12:112. PubMed
  38. Wells DK, et al. 2020. Cell. 183:818. PubMed
  39. Laustsen A, et al. 2021. Elife. 10:. PubMed
  40. Tripathi H, et al. 2020. J Mol Cell Cardiol. 149:95. PubMed
  41. Guo M, et al. 2021. Front Oncol. 11:632540. PubMed
  42. Brandsma AM, et al. 2021. Cancer Discov. . PubMed
  43. Brandsma AM, et al. 2021. Blood Cancer Discov. 2:484. PubMed
  44. Sefik E, et al. 2021. Nat Biotechnol. . PubMed
  45. Hasaart KAL, et al. 2022. iScience. 25:103736. PubMed
  46. Rosendahl Huber A, et al. 2022. STAR Protoc. 3:101361. PubMed
  47. Zhao NQ, et al. 2020. PLoS One. 15:e0238347. PubMed
  48. Tong M, et al. 2021. J Reprod Immunol. 145:103306. PubMed
  49. Babania O, et al. 2021. J Clin Lab Anal. 35:e23984. PubMed
  50. Ugawa M, et al. 2021. Elife. 10:. PubMed
  51. Fisch D, et al. 2022. Pathog Dis. 79:. PubMed
  52. Wang H, et al. 2022. J Neuroinflammation. 19:171. PubMed
  53. Yoshida R, et al. 2022. Cancer Res. :. PubMed
  54. Reitinger C, et al. 2022. Front Immunol. 13:970290. PubMed
  55. Herter JM, et al. 2022. Strahlenther Onkol. Online ahead of print. PubMed
  56. Yokoyama K, et al. 2022. Front Immunol. 13:1016914. PubMed
  57. Johnson RK, et al. 2022. Sci Rep. 12:19920. PubMed
  58. Liu J, et al. 2022. iScience. 25:105509. PubMed
  59. Woan KV, et al. 2021. Cell Stem Cell. 28:2062. PubMed
  60. Sefik E, et al. 2022. Nature. 606:585. PubMed
  61. Saber MM, et al. 2022. J Immunol Res. 2022:7219207. PubMed
  62. Chen W, et al. 2022. Front Immunol. 13:1046426. PubMed
  63. Zheng Y, et al. 2022. Proc Natl Acad Sci U S A. 119:e2121077119. PubMed
RRID
AB_314205 (BioLegend Cat. No. 302005)
AB_314206 (BioLegend Cat. No. 302006)

Antigen Details

Structure
Ig superfamily, transmembrane form (50-65 kD) or GPI-linked form (48 kD)
Distribution

NK cells, activated monocytes, macrophages, neutrophils

Function
Low affinity IgG Fc receptor, phagocytosis, ADCC
Ligand/Receptor
Aggregated IgG, IgG-antigen complex
Cell Type
Dendritic cells, Macrophages, Monocytes, Neutrophils, NK cells
Biology Area
Immunology, Innate Immunity
Molecular Family
CD Molecules, Fc Receptors
Antigen References

1. Fleit H, et al. 1982. P. Natl. Acad. Sci. USA 79:3275.
2. Stroncek D, et al. 1991. Blood 77:1572.
3. Wirthmueller U, et al. 1992. J. Exp. Med. 175:1381.

Gene ID
2214 View all products for this Gene ID
UniProt
View information about CD16 on UniProt.org

Related FAQs

Is our human Trustain FcX™ (cat# 422302) compatible with anti human CD16, CD32 and CD64 clones 3G8, FUN-2 and 10.1 respectively?

Yes

Go To Top Version: 2    Revision Date: 05/23/2014

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account